Amplification and clinicopathological significance of HER‑2 in Kazakh esophageal squamous cell carcinoma

Muhetaer,Aishanjiang; Niyaz,Madiniyet; Ainiwaer,Julaiti; Liwei,Zhang; Awut,Edris

doi:10.3892/mco.2020.2134

Amplification and clinicopathological significance of HER‑2 in Kazakh esophageal squamous cell carcinoma

Authors:
- Aishanjiang Muhetaer
- Madiniyet Niyaz
- Julaiti Ainiwaer
- Zhang Liwei
- Edris Awut
View Affiliations

Affiliations: Department of Thoracic Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, First Affiliated Hospital/Clinical Medicine Research Institute of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China
Published online on: September 11, 2020 https://doi.org/10.3892/mco.2020.2134
Article Number: 64
Copyright: © Muhetaer et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Amplification and overexpression of the human epidermal growth factor receptor‑2 (HER‑2) gene accelerates cell division and proliferation, and promotes tumor growth and metastasis in various malignant tumors. However, there are few reports on its influence and mechanism in esophageal cancer. The aim of the present study was to investigate the gene amplification and clinicopathological significance of HER‑2 in Kazakh esophageal squamous cell carcinoma (ESCC). HER‑2 gene amplification was detected in 70 esophageal cancer tissues using fluorescence in situ hybridization. The association between the HER‑2 gene amplification and the clinicopathological characteristics of patients with esophageal cancer was also analyzed. The amplification rate of the HER‑2 gene in patients with esophageal cancer was 54.2% (38/70). The results also revealed a positive association between the amplification rate of the HER‑2 gene in esophageal squamous cell carcinomas and the level of tissue differentiation, increasing gradually and significantly among the highly, moderately and poorly differentiated tissues (P<0.05). The amplification rate of the HER‑2 gene in patients with lymph node metastasis was higher than those without (P<0.05). There was no significant association between the amplification rate of the HER‑2 gene and any of the clinic pathological parameters, such as sex, age, depth of invasion and 3‑year survival, among patients (P>0.05). In conclusion, the amplification rate of the HER‑2 gene in patients with Kazakh ESCC was high. There was an association with various prognostic factors, including cancer differentiation and lymph node metastasis. HER‑2 gene expression levels may be considered as an indicator of poor prognosis in patients with ESCC in the clinical setting, and this may provide a basis of treatment for individualized targeted therapies.

View Figures

View References

1	Zheng R, Zeng H, Zhang S and Chen W: Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer. 36(66)2017.PubMed/NCBI View Article : Google Scholar
2	Gupta B and Kumar N: Worldwide incidence, mortality and time trends for cancer of the oesophagus. EurJ Cancer Prev. 26:107–118. 2017.PubMed/NCBI View Article : Google Scholar
3	Zhou YX, Zhou KM, Liu Q, Wang H, Wang W, Shi Y and Ma YQ: The effect of glut1 and c-myc on prognosis in esophageal squamous cell carcinoma of Kazakh and Han patients. Future Oncol. 14:1801–1815. 2018.PubMed/NCBI View Article : Google Scholar
4	Kim T, Grobmyer SR, Smith R, Ben-David K, Ang D, Vogel SB and Hochwald SN: Esophageal cancer: The five year survivors. J Surg Oncol. 103:179–183. 2011.PubMed/NCBI View Article : Google Scholar
5	Sagara Y, Kamada Y, Yamamoto Y, Tanaka M, Kubo M, Yamaguchi R, Nishimura R and Mitsuyama S: Study on the state of implementation of HER2 testing and positive ratios in patients with breast cancer in the Kyushu-Okinawa region of Japan. Breast Cancer. 19:315–320. 2012.PubMed/NCBI View Article : Google Scholar
6	Rosińska A, Rosiński G and Hołubowicz R: Advdnces on the HER-2/neu and oncotherapy. Acta Academiae Medicinae Cpaf 62, 2008.
7	Halling KC and Kipp BR: Fluorescence in situ hybridization indiagnostic cytology. Surg Oncol Clin N Am. 18:411–422. 2009.
8	Fritcher EG, Brankley SM, Kipp BR, Voss JS, Campion MB, Morrison LE, Legator MS, Lutzke LS, Wang KK, Sebo TJ and Halling KC: A comparison of conventional cytology,DNA ploidy analysis,and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with barrett's esophagus. Hum Pathol. 39:1128–1135. 2008.PubMed/NCBI View Article : Google Scholar
9	Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, Dankof A, Kölble K and Kristiansen G: Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation ofHER2gene status in breast carcinoma according to the guidelines of the American society of clinical oncology and the college of American pathologists. Virchows Arch. 451:19–25. 2007.PubMed/NCBI View Article : Google Scholar
10	Amin MB, Edge S, Greene F, (eds), et al: AJCC Esophageal and esophagogastric junction. AJCC Cancer Staging Manual. 8th edition. NewYork, Springer; pp185-202: 2017.
11	Huang JX, Zhao K, Lin M, Wang Q, Xiao W, Lin MS, Yu H, Chen P and Qian RY: HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. Oncol Lett. 6:13–18. 2013.PubMed/NCBI View Article : Google Scholar
12	Shroff GS, De Groot PM, Papadimitrakopoulou VA, Truong MT and Carter BW: Targeted therapy and immunotherapy in the treatment of non-small cell lung cancer. Radiol Clin North Am. 56:485–495. 2018.PubMed/NCBI View Article : Google Scholar
13	Alvarez RH, Valero V and Hortobagyi GN: Emerging targeted therapies for breast cancer. J Clin Oncol. 28:3366–3379. 2010.PubMed/NCBI View Article : Google Scholar
14	Lin CY, Yang SJ, Peng CL and Shieh MJ: Panitumumab-Conjugated and platinum-cored pH-sensitive apoferritin nanocages for colorectal cancer-targeted therapy. ACS Appl Mater Interfaces. 21:6096–6106. 2018.PubMed/NCBI View Article : Google Scholar
15	Vu T, Sliwkowski MX and Claret FX: Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta. 1846:353–365. 2014.PubMed/NCBI View Article : Google Scholar
16	Gutierrez CC and Schiff RR: HER2: Biology, detection, and clinical implications. Arch Pathol Lab Med. 135:55–62. 2011.PubMed/NCBI View Article : Google Scholar
17	Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, Yu BH and Du YQ: Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 17:1501–1506. 2011.PubMed/NCBI View Article : Google Scholar
18	Li HH, Ma F, Zeng X, Wang JY, Yuan P, Fan Y and Xu BH: Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics. Zhonghua Yi Xue Za Zhi. 91:76–80. 2013.(In Chinese).
19	Koo JS and Kim SH: EGFR and HER-2 status of non-small cell lung cancer brain metastasis and corresponding primary tumor. Neoplasma. 58:27–34. 2011.PubMed/NCBI View Article : Google Scholar
20	Bouché O and Penaultllorca F: HER-2 and gastric cancer: A novel therapeutic target for trastuzumab. Bull Cancer. 97:1429–1440. 2010.PubMed/NCBI View Article : Google Scholar : (In French).
21	Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA and Soares FA: Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistr. BMC Cancer. 7(9)2009.PubMed/NCBI View Article : Google Scholar
22	Wei Q, Chen L, Sheng L, Nordgren H, Wester K and Carlsson J: EGFR, HER-2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 31:493–499. 2007.PubMed/NCBI
23	Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, et al: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 20:120–129. 2007.PubMed/NCBI View Article : Google Scholar
24	Zhan N, Dong WG, Tang YF, Wang ZS and Xiong CL: Analysis of HER-2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 29:933–940. 2012.PubMed/NCBI View Article : Google Scholar
25	Niemiec JA, Adamczyk A, Małecki K, Majchrzyk K and Ryś J: Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/P-cadherin, and MMP-2 expression in early-stage invasive ductal breast cancer. Appl Immunohistochem Mol Morphol. 20:550–560. 2012.PubMed/NCBI View Article : Google Scholar